Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy
Open Access
- 15 December 2001
- journal article
- Published by American Society of Hematology in Blood
- Vol. 98 (13) , 3846-3848
Abstract
The feasibility and efficacy of a combination of thalidomide, cyclophosphamide, etoposide, and dexamethasone were studied in 56 patients with poor-prognosis multiple myeloma. Of 50 patients evaluable for response, 4% achieved complete response (CR), 64% partial response (PR), 18% minimal response (MR), 6% stable disease (SD), and 8% progressive disease (PD), resulting in an objective response rate (≥ MR) of 86.0% (76.7% overall objective response rate in intent-to-treat analysis; n = 56). Subsequent to successful remission induction, 18 patients received autologous or allogeneic stem cell transplantation. The median progression-free survival in all patients was 16 months. The median overall survival time could not be calculated, since the last observed death occurred after 16 months of follow-up (median follow-up of 14 months) with a corresponding estimated survival probability of 55%. Severe adverse effects (World Health Organization III/IV) included infectious complications (35.7%) and cardiovascular events (7.1%). The data suggest that Thal improves antitumor activity of salvage chemotherapy regimens in poor-prognosis multiple myeloma.Keywords
This publication has 12 references indexed in Scilit:
- Antitumor Activity of Thalidomide in Refractory Multiple MyelomaNew England Journal of Medicine, 1999
- High-Dose Melphalan With Autotransplantation for Refractory Multiple Myeloma: Results of a Southwest Oncology Group Phase II TrialJournal of Clinical Oncology, 1999
- Paclitaxel as the Initial Treatment of Multiple MyelomaAmerican Journal of Clinical Oncology, 1998
- CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONBritish Journal of Haematology, 1998
- Primary therapy of multiple myeloma with paclitaxel (Taxol)Annals of Oncology, 1994
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences, 1994
- The Treatment of Multiple MyelomaNew England Journal of Medicine, 1994
- Cyclophosphamide and etoposide therapy with GM‐CSF for VAD‐resistant multiple myelomaBritish Journal of Haematology, 1993
- Effective Treatment of Advanced Multiple Myeloma Refractory to Alkylating AgentsNew England Journal of Medicine, 1984
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958